New scan could reveal hidden lung damage in TB survivors
NCT ID NCT07077213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a special PET scan tracer called 18F-FAPI-74 can detect scarring (fibrosis) in the lungs of people with active tuberculosis. About 30 adults with confirmed TB will get the tracer and a whole-body PET/CT scan during and after treatment. The goal is to see if this scan can spot fibrosis better than standard imaging, which could help doctors understand and manage long-term lung damage from TB.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-FAPI-74 (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a better way to detect and monitor lung scarring in tuberculosis patients, helping doctors assess long-term lung damage.
- What could go wrong
- This is a small, early-phase study with only 30 participants. The tracer may not clearly show scarring, and results may not apply to all TB patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Males and female members of all races and ethnic groups are eligible for this trial and encouraged to participate.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: Patients may be enrolled into this protocol only if all the following inclusion criteria are met: * Greater than or equal to 18 years of age * Culture confirmation of M. tuberculosis, or sputum positive by molecular testing (GeneXpert). * Imaging evidence of suspected M. tuberculosis disease involving lung, and possible additional other sites of involvement. Modalities can include any imaging modality such as chest x-ray, CT, ultrasound, MRI, 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (\[18F\]FDG) PET/CT, bone scan. * TB treatment initiation within 6-weeks by the time of the study PET/CT scan OR within 6-weeks after receiving 6-months of TB treatments. Using this approach, we will be able to assess fibrosis in TB patients at treatment initiation as well as having received TB treatments. The same patient may be re-consented for a scan at the later time-point. * Subject is willing to give written informed consent. * Subject is willing and able to comply with the protocol for the duration of the study including undergoing scheduled visits and study procedures. * Screening clinical laboratory values must be within normal limits or judged not clinically significant by the investigator. * Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the radiotracer administration. * Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Exclusion criteria: Patients will be excluded from enrollment if any of the following apply: * Inadequate venous access (two antecubital or equivalent venous access sites are required for study drug injection and pharmacokinetics (PK) blood sampling, respectively) * Lactating females * Administered a radioisotope within 5 physical half-lives as part of a research study prior to study enrollment. * Determined to have prior (external) radiation exposure from research studies which will exceed Radioactive Drug Research Committee (RDRC) annual radiation exposure limit of 5 rems. * Any medical condition that in the judgment of the investigator would make the patient inappropriate for entry into this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tuberculosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Can a 4-Month drug cocktail cure TB as well as 6 months?
- Can simple sputum and urine tests catch tuberculosis earlier?
- Can a common virus be turned into a TB vaccine? scientists test VIR-1778
- Fish oil meets TB drugs: can Omega-3 help clear infection faster?
- Can starting TB treatment immediately save lives in HIV sepsis?